Want to see IN:ONESOURCE full AI Analyst Report?
ONESOURCE Stock Chart & Stats
₹1653.40
₹35.00(2.12%)
At close: 4:00 PM EDT
₹1653.40
₹35.00(2.12%)
Day’s Range― - ―
52-Week Range₹1,075.00 - ₹1,989.70
Previous CloseN/A
Volume717.16K
Average Volume (3M)3.94K
Market Cap
₹185.97B
Enterprise Value₹222.64K
Total Cash (Recent Filing)₹1.80B
Total Debt (Recent Filing)₹12.95B
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.53
Shares Outstanding114,669,990
10 Day Avg. Volume3,856
30 Day Avg. Volume3,937
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.89
Price to Sales (P/S)11.87
P/FCF Ratio-24.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)36.13
Revenue Forecast (FY)₹22.53B
Bulls Say, Bears Say
Bulls Say
Top-line MomentumA ~77% revenue surge in FY2026 indicates meaningful demand expansion and successful commercialization or market penetration. Sustained top-line momentum provides capacity to scale operations, invest in R&D and amortize fixed costs, supporting durable growth if margins and cash conversion improve.
Manageable Historical LeverageA historically low debt-to-equity (~0.16 in FY2025) and sizeable equity base give the company financial flexibility to fund operations or strategic initiatives. This cushion helps absorb near-term losses and supports access to capital without immediate solvency pressure, a durable balance-sheet advantage.
Established Operational ScaleA workforce of ~1,412 combined with accelerating revenue suggests established operational capacity and product/service delivery scale. Scale supports reproducible operations, distribution capability and R&D/resource depth, helping sustain market position as revenues continue to expand over months.
Bears Say
Negative Operating Cash FlowConsecutive negative operating cash flows across FY2025–FY2026 indicate the business is not generating cash from core operations. Persistent cash burn undermines self-funding, forces reliance on external financing, and raises execution risk for growth initiatives over the next several months if not reversed.
Worsening ProfitabilityA shift from near breakeven to a large net loss and sharply lower EBIT signals margin compression and cost or mix issues. If elevated expenses or low-margin growth persist, profitability recovery will be difficult, limiting free cash generation and constraining strategic options in the medium term.
Rising Debt Alongside LossesIncreasing debt concurrent with deteriorating earnings raises leverage and refinancing risk. Even if absolute leverage remains moderate, the trend of rising borrowings while posting losses elevates liquidity and covenant concerns and reduces resilience to operational setbacks over the coming months.
OneSource Specialty Pharma Limited News
ONESOURCE FAQ
What was OneSource Specialty Pharma Limited’s price range in the past 12 months?
OneSource Specialty Pharma Limited lowest stock price was ₹1075.00 and its highest was ₹1989.70 in the past 12 months.
What is OneSource Specialty Pharma Limited’s market cap?
OneSource Specialty Pharma Limited’s market cap is ₹185.97B.
When is OneSource Specialty Pharma Limited’s upcoming earnings report date?
OneSource Specialty Pharma Limited’s upcoming earnings report date is Nov 17, 2026 which is in 106 days.
How were OneSource Specialty Pharma Limited’s earnings last quarter?
OneSource Specialty Pharma Limited released its earnings results on Jul 24, 2026. The company reported ₹2.6 earnings per share for the quarter, missing the consensus estimate of ₹5.3 by -₹2.7.
Is OneSource Specialty Pharma Limited overvalued?
According to Wall Street analysts OneSource Specialty Pharma Limited’s price is currently Overvalued.
Does OneSource Specialty Pharma Limited pay dividends?
OneSource Specialty Pharma Limited does not currently pay dividends.
What is OneSource Specialty Pharma Limited’s EPS estimate?
OneSource Specialty Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OneSource Specialty Pharma Limited have?
OneSource Specialty Pharma Limited has 114,669,990 shares outstanding.
What happened to OneSource Specialty Pharma Limited’s price movement after its last earnings report?
OneSource Specialty Pharma Limited reported an EPS of ₹2.6 in its last earnings report, missing expectations of ₹5.3. Following the earnings report the stock price went down -0.024%.
Which hedge fund is a major shareholder of OneSource Specialty Pharma Limited?
Currently, no hedge funds are holding shares in IN:ONESOURCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts its operations internationally, with a footprint in India, Ireland, and the United States. It delivers comprehensive contract development and manufacturing (CDMO) services for biologics, encompassing all phases from preclinical and clinical development to commercial-scale supply. Its offerings extend to integrated drug-device systems such as pre-filled syringes, various pen injectors (including dial, push, and pull-push types for both variable and fixed doses), and autoinjectors. Furthermore, OneSource Specialty Pharma manufactures sterile injectable drugs and soft gelatin capsules, and provides specialized biologics solutions tailored for microbial and mammalian cell-line biopharmaceuticals, as well as for cell, gene, and RNA therapies. Established in 2007, the company, headquartered in Bengaluru, India, was formerly known as Stelis Biopharma Limited until its rebranding in February 2024.
Technical Analysis
Alembic Pharmaceuticals Limited
―
AstraZeneca Pharma India Limited
―
Eris Lifesciences Ltd
―
PFIZER LIMITED
―
Piramal Pharma Limited
―